Skip to Content

Curaleaf Holdings Inc

CURA: XTSE (CAN)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
CAD 23.40SgmMvvlwynr

Curaleaf: No Change to Outlook for Now as We Think New Jersey Adult-Use License Will Be Renewed

On April 13, the New Jersey Cannabis Regulatory Commission’s board denied renewal of Curaleaf’s cultivation and retail licenses for adult-use cannabis. Two adult-use dispensaries may need to halt sales by April 21, though a third dispensary that opened more recently and Curaleaf’s medical licenses are unaffected. The company gained access to the state’s legal recreational market when it opened in April 2022 and has since grown its cultivation and retail footprint in the state. The board’s ruling was a surprise to us, as it went against the commission’s own executive director’s recommendation and was the only renewal applicant to be denied. The market was surprised, with shares down over 7% on Friday, April 14.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CURA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center